Shenzhen Geno-Immune Medical Institute

Dual-Target CAR-T Therapy Shows Promise for Glioblastoma with 24.5-Month Median Survival

- A clinical trial combining PSMA and GD2 CAR-T cells achieved a median overall survival of 24.5 months in six patients with refractory or relapsed gliomas, significantly exceeding typical survival rates of 5-7 months. - All patients achieved clinical benefit with 50% complete response rate, while treatment was well-tolerated with manageable side effects including grade 1 cytokine release syndrome in half of patients. - Mathematical modeling studies suggest that lower CAR-T doses administered at longer intervals may optimize treatment effectiveness by maintaining sustained immune responses without depleting therapeutic cells. - Patients with lower tumor burden demonstrated superior outcomes, with 100% two-year survival compared to zero survival in high tumor burden cases, highlighting the importance of early intervention.